Möchten Sie immer auf dem neuesten Stand bleiben?

Phase 1 study builds on early signals of anti-tumor activity in patients with refractory T and B cell lymphomas Ipsoprubart, a first-in-class SIRP-targeting therapy, expands into T cell malignancies...

POSCO & Electra sign JDA and investment to test and qualify the technologies needed for commercial production of Electra's high-purity, clean iron.

$30M venture debt facility from J.P. Morgan will support Electra’s scale-up as the company prepares its first commercial clean iron facility.

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, a clinical stage biotechnology company pioneering therapies against novel targets for diseases in immunology and...

The SURPASS study is enrolling patients at research sites across the U.S. and Europe ELA026 targets signal regulatory proteins (SIRP) as a novel approach to treating the life-threatening...

Proceeds will fund a global pivotal trial of lead product candidate, ELA026, as a frontline treatment for secondary hemophagocytic lymphohistiocytosis (sHLH) Financing will also support indication...

ELA026 has demonstrated promising potential as a frontline treatment for patients with sHLH, a hyperinflammatory disease with high mortality and significant unmet medical need Electra has initiated...

BOULDER, Colo., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Electra, a clean iron company, today unveiled the site of its new demonstration facility in Jefferson County, Colorado. The 130,000 square foot...

BOULDER, Colo., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Electra, a clean iron company, and Interfer Edelstahl Group, a global steel and raw materials trader, have signed a memorandum of understanding...

BOULDER, Colo., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Today TIME named Electra CEO and Co-Founder Sandeep Nijhawan to the 2024 TIME100 Climate list, recognizing the 100 most innovative leaders driving...